Eli Lilly & Co. vs. Royalty Pharma plc Class A Ordinary Shares
LLY
Eli Lilly & Co.
$1184.83 +0.12%
VS RPRXRoyalty Pharma plc Class A Ordinary Shares
$57.99 -0.51%
Royalty Pharma plc Class A Ordinary Shares (RPRX) comes out ahead, leading on 6 of 11 compared factors.
Size & Scale
| LLY | RPRX | |
|---|---|---|
| Market Cap | $1.05 trillion | $25.96 billion |
| Revenue (TTM) | $79.67 billion | $2.54 billion |
| Net Income (TTM) | $26.71 billion | $1.35 billion |
LLY leads on 3 of 3 size & scale factors.
Valuation
| LLY | RPRX | |
|---|---|---|
| P/E Ratio | 39.77 | 30.85 |
| Price / Book | 31.14 | 2.65 |
| Price / Sales | 13.24 | 10.23 |
RPRX leads on 3 of 3 valuation factors.
Profitability
| LLY | RPRX | |
|---|---|---|
| Net Margin | 33.53% | 53.23% |
| Return on Equity | 78.84% | 13.79% |
LLY and RPRX split the profitability factors evenly.
Dividend
| LLY | RPRX | |
|---|---|---|
| Dividend Yield | 0.58% | 1.62% |
| Payout Ratio | 23.23 | 50.00 |
LLY and RPRX split the dividend factors evenly.
Risk & Sentiment
| LLY | RPRX | |
|---|---|---|
| Short Interest | 1.29% | 0.34% |
RPRX leads on 1 of 1 risk & sentiment factors.
Dig deeper: LLY overview, LLY financials, RPRX overview, RPRX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.